Myriad Genetics Jumps 36.94% on Prenatal Testing Business Sale to Labcorp
FROM THE WIRE · INVESTORIDEAS.COM
Myriad Genetics (NASDAQ: MYGN) soars 36.94% on news it will sell its Prenatal Health testing business to Labcorp for $210 million in cash.
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishA divestiture for 210 million dollars in cash, with a strong reaction in the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Myriad Genetics (MYGN) soars 36.94%.
- 02The company will sell its Prenatal Health testing business to Labcorp.
- 03The sale is valued at 210 million dollars in cash.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets